

Understanding Your PredictSURE IBD™ Results



① The course of Crohn's and ulcerative colitis vary greatly from person to person



② Your doctor has chosen to use PredictSURE IBD™ to help better understand your disease



③ Your doctor will discuss your result with you and how your risk may affect your disease activity



④ Your doctor will suggest the best treatment option for you

What is the PredictSURE IBD™ test and how does it work?

PredictSURE IBD™ is a blood test for newly diagnosed patients that provides information about the likely severity of your inflammatory bowel disease (IBD). The test measures 15 genes that have been shown to reliably predict whether IBD patients are at high-risk or low-risk of more active disease. This information will help your doctor determine the best treatment plan to manage your IBD.

Why has my doctor asked for the test to be done?

- IBD is unpredictable which can complicate the selection of the best treatment option.
- PredictSURE IBD™ clarifies the disease course you may experience, and along with other test results, helps your doctor select the best treatment plan for you.
- The goal is to provide the best treatment for you to reduce the disease impact on your life.

Will I have to do the PredictSURE IBD™ test on a regular basis?

- No, this test is only required at the time of diagnosis. You will not need to have the test again.

What was the result of my test?

- Your doctor has the result and will discuss it and the treatment plan with you.

High and low risk - what does it mean?

- PredictSURE IBD™ sorts people into high and low risk subgroups, which relate to disease activity.
- "High-risk" patients are more likely to experience multiple flares within the first 12 months after diagnosis.
- "Low-risk" patients are less likely to experience multiple flares within the first 12 months.
- If you are high-risk, you may be monitored more closely and prescribed stronger treatment earlier, potentially increasing the chance of achieving remission, and reducing the risk of future surgeries.
- If you are low-risk, you can feel more confident that starting with less aggressive therapies is appropriate.

FOR IN VITRO DIAGNOSTIC USE ONLY. The PredictSURE IBD™ prognostic test has been developed by Predictimmune Ltd, UK for prognostication purposes. The test was developed on newly diagnosed, treatment naïve IBD patients (55% Crohn's disease; 45% ulcerative colitis). It is not intended to be used to predict patient response to individual treatments. The testing laboratory is responsible for executing the test and reporting the patient-specific results. Predictimmune Ltd retain responsibility for the development of the test and performance of the test under conditions defined in the test IFU. *Inf: LOC730227, NUDT7, P2RY14, IL18RAP, GZMH, IFI44L, GBP5, FCRL5, LY96, HP, VTRNA1-1, TRGC2/TARP, LGALS1, GZMK, TRGV3. Ref: CDV3, 18S